A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
Sabue MulanguLori E DoddRichard T DaveyOlivier Tshiani MbayaMichael ProschanDaniel MukadiMariano Lusakibanza ManzoDidier B NzoloAntoine Tshomba OlomaAugustin IbandaRosine AliSinaré CoulibalyAdam C LevineRebecca GraisJanet DiazHenry Clifford LaneJean-Jacques Muyembe-Tamfumnull nullBilly SivaheraModet CamaraRichard KojanRobert WalkerBonnie Dighero-KempHuyen CaoPhilippe MukumbayiPlacide Mbala-KingebeniSteve AhukaSarah AlbertTyler BonnettIan CrozierMichael DuvenhageCalvin ProffittMarc TeitelbaumThomas MoenchJamila AboulhabKevin BarrettKelly CahillKatherine ConeRisa EckesLisa HensleyBetsey HerpinElizabeth HiggsJulie LedgerwoodJerome PiersonMary SmolskisYdrissa SowJohn TierneySumathi SivapalasingamWendy HolmanNikki GettingerDavid ValléeJacqueline Nordwallnull nullPublished in: The New England journal of medicine (2019)
Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD. Scientifically and ethically sound clinical research can be conducted during disease outbreaks and can help inform the outbreak response. (Funded by the National Institute of Allergy and Infectious Diseases and others; PALM ClinicalTrials.gov number, NCT03719586.).